Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 32Triple Negative Breast Neoplasms 26Carcinoma, Transitional Cell 9Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 8Urinary Bladder Neoplasms 7Lung Neoplasms 4Endometrial Neoplasms 3Brain Neoplasms 3Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Paclitaxel 6pembrolizumab 3Cisplatin 3Carboplatin 3Biopsy 3adavosertib 2Trastuzumab 2Magnetic Resonance Spectroscopy 2Fulvestrant 2Doxorubicin 2ulixertinib 1tucatinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1selinexor 1sapanisertib 1sacituzumab govitecan 1relugolix 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1niraparib 1larotrectinib 1ipatasertib 1erdafitinib 1dostarlimab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Neoplasms × sacituzumab govitecan × 1 year × Clear all
NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Recruiting
54 enrolled
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡